Genentech Bio Signed a Discovery Collaboration with Kronos Bio to Advance Novel Therapies Against Transcriptional Targets in Oncology
AdAlta Collaborated with GPCR Therapeutics for Novel Therapies to Treat CancerShots:
- Kronos Bio to receive $20M up front and additional fees upon achievement of milestones where $177M for 1st program, ~$100M in sales milestones for 1st licensed product per Hit program along with royalties. The deal may reach ~$554M if all milestones are met
- The companies will initially collaborate on 2 discovery research programs in oncology with each one focused on a transcription factor, discover small-molecule GLP-Tox-ready candidates that modulate transcription factor targets (selected by Genentech)
- Kronos Bio will lead discovery & research activities and will use its drug discovery platform, incl. the small molecule microarray. Genentech to get an exclusive right for preclinical, clinical development & commercialization of compounds & will use also Kronos Bio’s expertise
Ref: Globenewswire | Image: Genentech Bio
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.